Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 3,580 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: patch Clear all

Conditions: Intracranial Aneurysm
Interventions: Penumbra Smart Coil, Penumbra Coil 400TM (PC400), Penumbra Occlusion DeviceTM(POD); Device
Lead sponsor: Penumbra Inc.; Industry
Eligibility: Not listed
Enrollment: 995 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 71
States / cities: Dothan, Alabama • Mesa, Arizona • Phoenix, Arizona + 62 more

Conditions: Gastrointestinal Diseases, Ileus Paralytic, Ileus
Interventions: G-tech WPS; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Smoking Cessation
Interventions: Motivational Interviewing (MI), Nicotine Replacement Therapy (NRT), Nicotine Lozenge, Message Framing, saliva sample; Behavioral · Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 50 Years to 80 Years
Enrollment: 807 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 18
States / cities: Los Angeles, California • Walnut Creek, California • La Grange, Georgia + 14 more

Conditions: Smoking, Homeless Persons
Interventions: Bupropion, Nicotine replacement therapy, Contingency Management; Drug · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Dysphagia, Stroke
Interventions: Microphone device; Device
Lead sponsor: Emory University; Other
Eligibility: 40 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Chronic Rhinitis
Interventions: NEUROMARK System; Device
Lead sponsor: Neurent Medical; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 10
States / cities: Birmingham, Alabama • California City, California • Temecula, California + 7 more

Conditions: Solid Tumors, Lymphoma
Interventions: Ulevostinag, Pembrolizumab; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Santa Monica, California + 5 more

Conditions: Coronary Artery Disease, Atherosclerosis
Interventions: rotational atherectomy, cutting balloon, plain old balloon; Procedure · Device
Lead sponsor: Samin Sharma, M.D., F.A.C.C., M.S.C.A.I.; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: New York, New York • Roslyn, New York

Conditions: Breast Diseases
Interventions: Not listed
Lead sponsor: MetriTrack, Inc.; Industry
Eligibility: 21 Years to 70 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Solid Tumor
Interventions: Atezolizumab, GDC-0919; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 10
States / cities: Scottsdale, Arizona • Santa Monica, California • Aurora, Colorado + 6 more

Conditions: Barrett Esophagus, Barrett Adenocarcinoma, Esophagus Neoplasm
Interventions: Endoscopic mucosal resection, Endoscopic submucosal dissection; Procedure
Lead sponsor: Universitätsklinikum Hamburg-Eppendorf; Other
Eligibility: 18 Years to 99 Years
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Cystitis, Interstitial, Ulcer
Interventions: LiRIS®, LiRIS Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 17
States / cities: Murrieta, California • Vacaville, California • Farmington, Connecticut + 14 more

Conditions: Type 1 Diabetes
Interventions: PassPort(R) Transdermal Insulin Delivery System; Other
Lead sponsor: Altea Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: 387 Technology Circle, NW, Suite 100, Atlanta, Georgia

Conditions: Peripheral Vascular Disease
Interventions: Complete SE Vascular Stent System; Device
Lead sponsor: Medtronic Endovascular; Industry
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 4
States / cities: Fremont, California • Gainesville, Florida • Ocala, Florida + 1 more

Conditions: Cervix Cancer, Cervix Lesion
Interventions: Liger Medical Thermocoagulator; Device
Lead sponsor: PATH; Other
Eligibility: 30 Years to 49 Years · Female only
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Osteoarthritis of the Knee
Interventions: Diclofenac Sodium Active Topical Patch 1, Diclofenac Sodium Active Topical Patch 2, Placebo patch; Drug
Lead sponsor: Noven Pharmaceuticals, Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Jersey City, New Jersey

Conditions: Ovarian Cancer, Fallopian Tube, Primary Peritoneal
Interventions: Positron Emission Tomography, 18F-Fluoro-2-deoxy-D-lucose, Cytoreductive surgery; Procedure · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 19 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Sclerosis
Interventions: Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®), Placebo; Drug
Lead sponsor: Synthon BV; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 794 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 7
States / cities: Irvine, California • Port Charlotte, Florida • Sunrise, Florida + 4 more

Conditions: Melanoma
Interventions: EGIR Tape; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Motion Sickness
Interventions: Scopolamine Nasal Gel, Placebo; Drug · Other
Lead sponsor: Repurposed Therapeutics, Inc.; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Peanut Allergy
Interventions: Viaskin Peanut 50 mcg, Viaskin Peanut 100 mcg, Viaskin Peanut 250 mcg, Viaskin Placebo; Biological
Lead sponsor: DBV Technologies; Industry
Eligibility: 6 Years to 55 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 10
States / cities: San Diego, California • Stanford, California • Chicago, Illinois + 6 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: iSABR, 25 Gray in 1 fraction for small peripheral tumors, iSABR, 50 Gray in 4 fractions for medium peripheral tumors, iSABR, 54 Gray in 3 fractions for large peripheral tumors, iSABR, 40 Gray in 4 fractions for small central tumors, iSABR, 50 Gray in 4 fractions for medium central tumors, iSABR, 60 Gray in 8 fractions for large central tumors; Radiation
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 2
States / cities: Stanford, California • Seattle, Washington

Conditions: Dysplastic Nevi
Interventions: Saucerization biopsy; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Postoperative Pain, Obstetric Pain, Opioid Use
Interventions: Lidocaine patch, Placebo patch; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 52 Years · Female only
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

Assessment of the Embolization of Neurovascular Lesions Using the Penumbra Smart Coil

Myoelectric Activity Following Colorectal Surgery and Return of Bowel Function

Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites

Contingency Management for Smoking Cessation in Homeless Smokers

Dysphagia Study Using Novel Microphone Device

Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects With Chronic Rhinitis (PARAGON)

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

Rotational Atherectomy Combined With Cutting Balloon to Optimize Stent Expansion in Calcified Lesions

Effect of Body Position and Probe Position on the Localization of Breast Mass

A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors

Neoplastic Barrett Esophagus: Endoscopic Piecemeal vs. En Bloc Resection

A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions

Transdermal Basal Insulin Patch Study in Type 1 Diabetes

The Complete® SE SFA Study for the Treatment of SFA/PPA Lesions

Honduras Liger Thermocoagulator Study

A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis

Intraoperative Detection of Lesions Using PET (Positron Emission Tomography) Probe During Secondary Cytoreductive Surgery for Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer

Efficacy and Safety of GTR in Comparison to Copaxone®

Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells

The Prevention and Treatment of Nausea Associated With Motion Sickness

Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy

Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)

Prospective Study of 2 mm Margins for the Biopsy of Dysplastic Nevi

Lidocaine Patches After Cesarean Section